EP1077968A1 - Derives de naphto[2,3-b]heteroar-4-yle - Google Patents

Derives de naphto[2,3-b]heteroar-4-yle

Info

Publication number
EP1077968A1
EP1077968A1 EP99920418A EP99920418A EP1077968A1 EP 1077968 A1 EP1077968 A1 EP 1077968A1 EP 99920418 A EP99920418 A EP 99920418A EP 99920418 A EP99920418 A EP 99920418A EP 1077968 A1 EP1077968 A1 EP 1077968A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
dimethyl
alkyl
hydrogen
naphtho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99920418A
Other languages
German (de)
English (en)
Inventor
Paul Jeffrey Dollings
Arlene Joan Dietrich
Jay Edward Wrobel
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1077968A1 publication Critical patent/EP1077968A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

L'invention concerne des composés de la formule structurelle (I) dans laquelle R1 et R2 représentent chacun indépendamment, hydrogène, nitrile, nitro, amino, alkylamino C¿1-6?, dialkylamino comprenant 1 à 6 atomes de carbone par groupe alkyle, cycloalkyl-amino C3-8, alkyle C1-6, perfluoroalkyle C1-6, halogène, cycloalkyle C3-8, thiényle, furyle, phényle ou phényle mono-, di- ou tri-substitué par halogène, hydroxy, alkyle C1-6, perfluoroalkyle C1-6, alcoxy C1-6, ou perfluoroalcoxy C1-6; R?3 et R4¿ représentent chacun indépendamment hydrogène, alkyle C¿1-6?, perfluoroalkyle C1-6, hydroxyalkyle C1-6, aminoalkyle C1-6, acyle C2-7; R?5¿ représente hydrogène, halogène, alkyle C¿1-6?, perfluoroalkyle C1-6, nitrile, alcoxy C1-6, aryloxy, arylalcoxy C2-12, arylsulfanyle; W représente S, O ou NR?9; R9¿ représente hydrogène ou alkyle C¿1-6?, X représente O, -NR?6¿-, ou (CH¿2?)pNR?6-; R6¿ représente hydrogène, ou alkyle C¿1-6?; p vaut 1 à 4; Y représente méthylène, carbonyle, -SO2-, ou SO-; Z représente phényle, hétéroaryle ou naphtyle; R?7 et R8¿ représentent chacun indépendamment hydrogène, carboxyle, acyle C¿2-7?, hydroxyle, hydroxyalkyle C1-6, hydroxyalcanoyle C1-6, alcoxy C1-6, perfluoroalcoxy C1-6, alcoxycarbonyle C2-7, perfluoroalcoxycarbonyle C2-7, alkyle C1-6, perfluoroalkyle C1-6, aryle, aryloxy, aryloxycarbonyle, hétéroaryloxycarbonyle, arylalcoxy C6-12, héréroaryle, alcanoyloxy C1-6, perfluoroalcanoyloxy C1-6, hétéroaroyloxy, aroyloxy, tétrazolyle, mercapto, nitrile, amino, carbamoyle, aminoalkyle C1-6, -NHSO2CF3, carboxyaldéhyde, halogène, nitro, acylamino, ou pyrimidyle éventuellement substitué par mercapto, 3-hydroxy-cyclobut-3-ène-4-yl-1,2-dione, ou acide tétronique. L'invention concerne également des sels de ces composés, acceptables sur le plan pharmacologique. Ces sels et composés sont utiles dans le traitement de troubles métaboliques associés à l'insulinorésistance ou à l'hyperglycémie.
EP99920418A 1998-05-12 1999-05-10 Derives de naphto[2,3-b]heteroar-4-yle Withdrawn EP1077968A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76446 1993-06-14
US7644698A 1998-05-12 1998-05-12
PCT/US1999/010210 WO1999058522A1 (fr) 1998-05-12 1999-05-10 Derives de naphto[2,3-b]heteroar-4-yle

Publications (1)

Publication Number Publication Date
EP1077968A1 true EP1077968A1 (fr) 2001-02-28

Family

ID=22132072

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99920418A Withdrawn EP1077968A1 (fr) 1998-05-12 1999-05-10 Derives de naphto[2,3-b]heteroar-4-yle

Country Status (8)

Country Link
EP (1) EP1077968A1 (fr)
JP (1) JP2002514639A (fr)
CN (1) CN1308625A (fr)
AR (1) AR019842A1 (fr)
AU (1) AU3791699A (fr)
CA (1) CA2330555A1 (fr)
TW (1) TW446704B (fr)
WO (1) WO1999058522A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
CA2469228A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
CN100334088C (zh) * 2003-05-15 2007-08-29 霍夫曼-拉罗奇有限公司 作为蛋白质酪氨酸磷酸酶抑制剂的二氨基吡咯并喹唑啉化合物
US7226915B2 (en) 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005035551A2 (fr) 2003-10-08 2005-04-21 Incyte Corporation Inhibiteurs de proteines se liant a des molecules phosphorylees
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
PE20070458A1 (es) 2005-09-14 2007-07-05 Takeda Pharmaceutical Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3239170B1 (fr) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ265692A (en) * 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
WO1997008126A1 (fr) * 1995-08-28 1997-03-06 American Home Products Corporation Acides phenoxyacetiques en tant qu'inhibiteurs de l'aldose reductase et agents anti-hyperglycemiants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9958522A1 *

Also Published As

Publication number Publication date
TW446704B (en) 2001-07-21
CA2330555A1 (fr) 1999-11-18
CN1308625A (zh) 2001-08-15
AU3791699A (en) 1999-11-29
WO1999058522A1 (fr) 1999-11-18
AR019842A1 (es) 2002-03-20
JP2002514639A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
WO1999058522A1 (fr) Derives de naphto[2,3-b]heteroar-4-yle
AU756337B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
US6444670B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia
EP1077967B1 (fr) Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6369072B2 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077970A1 (fr) 11-ARYL-BENZO B]NAPHTO 2,3-D]FURANES ET 11-ARYL-BENZO b]NAPHTO 2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIE
US6121271A (en) Naphtho[2,3-B]heteroar-4-yl derivatives
US6683107B2 (en) Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6110962A (en) 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
IE64995B1 (en) Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome
US6057316A (en) 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
US6001867A (en) 1-aryl-dibenzothiophenes
US6221902B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US4931459A (en) Method for treating acute respirator distress syndrome
US6063815A (en) Benzopenones useful in the treatment of insulin resistance and hyperglycemia
EP1077966B1 (fr) Acides biphenyl-sulfonyl-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
MXPA00011088A (en) Naphtho[2,3-b]heteroar-4-yl derivatives
US6310081B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6340676B2 (en) 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
MXPA00011091A (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
MXPA00011085A (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
CZ20004182A3 (cs) Deriváty benzothiofenu, benzofuranu a indolu
MXPA00011086A (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011089A (en) 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001106;LT PAYMENT 20001106;LV PAYMENT 20001106;RO PAYMENT 20001106;SI PAYMENT 20001106

17Q First examination report despatched

Effective date: 20011206

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030603

RTI1 Title (correction)

Free format text: NAPHTHO??2,3-B HETEROAR-4-YL DERIVATIVES